Form 4: iTeos Therapeutics CFO Acquires 5,000 Shares

iTeos Therapeutics' Chief Financial Officer, Matthew Gall, purchased 5,000 shares of common stock at a price of $7.727 per share on November 19, 2024.

Summary

• Matthew Gall, the Chief Financial Officer of iTeos Therapeutics, Inc., acquired 5,000 shares of the company's common stock on November 19, 2024.
• The purchase price was $7.727 per share.
• Following this transaction, Mr. Gall directly owns 65,429 shares of iTeos Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. It indicates confidence from the CFO but is not a major event.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• Form 4 filings are a standard practice for reporting changes in beneficial ownership by company insiders, and iTeos Therapeutics is adhering to these regulations.

Stakeholder Impact

• The share purchase by the CFO may be viewed positively by shareholders as a sign of confidence in the company's prospects.

Key Dates

Keywords

iTeos Therapeutics, Matthew Gall, insider trading, share purchase, common stock, CFO